Investigation of beta-cell function by receiving semaglutide among inpatints with type 2 diabetes.
Not Applicable
Recruiting
- Conditions
- type2 diabetes
- Registration Number
- JPRN-UMIN000042478
- Lead Sponsor
- Saiseikai Yokohamashi Nanbu Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with severe liver dysfunction 2) Patients with severe renal dysfunction(eGFR<30ml/min/1.73) 3) Patients with fasting serum CPR <0.5 or postprandial serum CPR <1.0 4) Patinet with diabetic ketoacidosis 5) Patient with infection 6) Patients taking steroid 7) Patients with malignant tumor currently undergoing treatment 8) Pregnant or lactating woman 9) Other patients who are judged to be unsuitable as subjects by the judgment of a doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The difference of insulin secretory ability (such as urine CPR, serum C-peptide and CPRindex in fasting, AUC of serum C-peptide during the GST) in three months after discharge between type2 diabetic inpatients who receive semaglutide or not.
- Secondary Outcome Measures
Name Time Method